Product Hopping in the Drug Industry — Lessons from Albuterol

Product hops to albuterol inhalers containing hydrofluoroalkane rather than chlorofluorocarbons cost payers and patients billions of dollars. Without patent and regulatory reform, this pattern is likely to be repeated.